Apomorphine in the treatment of Parkinson disease and other movement disorders

被引:0
作者
Gunzler, Steven A. [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Univ Hosp,Movement Disorders Ctr, Case Med Ctr,Neurol Inst, Cleveland, OH 44106 USA
关键词
apomorphine; dopamine agonist; movement disorders; Parkinson disease; RESTLESS LEGS SYNDROME; DEEP BRAIN-STIMULATION; NEUROLEPTIC MALIGNANT SYNDROME; TERM-FOLLOW-UP; SUBCUTANEOUS APOMORPHINE; DOUBLE-BLIND; MOTOR FLUCTUATIONS; HUNTINGTONS-CHOREA; L-DOPA; DOPAMINERGIC RESPONSIVENESS;
D O I
10.1517/14656560902828344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. Objective: The clinical literature is summarized with particular focus on randomized controlled studies of apomorphine in the treatment of Parkinson disease. Methods: After reviewing the pharmacologic properties of apomorphine, the English language literature is summarized with particular attention on articles resulting from a Medline search of apomorphine and Parkinson disease limited to randomized controlled studies. Other formulations and indications for treatment of movement disorders are also discussed. Results/conclusion: Subcutaneous apomorphine is well tolerated when co-administered with trimethobenzamide or domperidone premedication. it has a unique efficacy as a 'rescue' medication owing to its rapid onset of action. Subcutaneous infusion, although not an approved route of administration in the US, provides more continuous dopaminergic stimulation and, therefore, ameliorates dyskinesia and motor fluctuations.
引用
收藏
页码:1027 / 1038
页数:12
相关论文
共 50 条
  • [31] Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations
    Carbone, Federico
    Djamshidian, Atbin
    Seppi, Klaus
    Poewe, Werner
    CNS DRUGS, 2019, 33 (09) : 905 - 918
  • [32] Lesion therapy for Parkinson's disease and other movement disorders: Update and controversies
    Okun, MS
    Vitek, JL
    MOVEMENT DISORDERS, 2004, 19 (04) : 375 - 389
  • [33] EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
    Dafsari, Haidar S.
    Martinez-Martin, Pablo
    Rizos, Alexandra
    Trost, Maja
    dos Santos Ghilardi, Maria Gabriela
    Reddy, Prashanth
    Sauerbier, Anna
    Petry-Schmelzer, Jan Niklas
    Kramberger, Milica
    Borgemeester, Robbert W. K.
    Barbe, Michael T.
    Ashkan, Keyoumars
    Silverdale, Monty
    Evans, Julian
    Odin, Per
    Fonoff, Erich Talamoni
    Fink, Gereon R.
    Henriksen, Tove
    Ebersbach, Georg
    Pirtosek, Zvezdan
    Visser-Vandewalle, Veerle
    Antonini, Angelo
    Timmermann, Lars
    Chaudhuri, K. Ray
    Schrag, Anette
    Weintraub, Daniel
    Barone, Paolo
    Brooks, David J.
    Brown, Richard G.
    Jenner, Peter
    Jeon, B.
    Lyons, Kelly
    Pavese, Nicola
    Politis, Marios
    Postuma, Ronald B.
    Schapira, Anthony
    Stocchi, Fabrizio
    Tsuboi, Yoshio
    MOVEMENT DISORDERS, 2019, 34 (03) : 353 - 365
  • [34] Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders
    Deputy, Stephen R.
    Tilton, Ann H.
    NEUROTHERAPEUTICS, 2020, 17 (04) : 1713 - 1723
  • [35] Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease
    Courty, E
    Durif, F
    Zenut, M
    Courty, P
    Lavarenne, J
    CLINICAL NEUROPHARMACOLOGY, 1997, 20 (02) : 140 - 147
  • [36] Use of apomorphine in Parkinson's disease
    Stocchi, Fabrizio
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 5) : S383 - S386
  • [37] Use of apomorphine in Parkinson’s disease
    Fabrizio Stocchi
    Neurological Sciences, 2008, 29 : 383 - 386
  • [38] Clinical experience in the treatment of motor fluctuation in Parkinson's disease. Delphi consensus of a group of experts in movement disorders
    Rodriguez-Sanz, Ana
    Pena-Llamas, Esteban
    Alonso-Canovas, Araceli
    Alonso-Frech, Fernando A.
    Borrue-Fernandez, Carmen
    Jose Catalan, M.
    Fanjul-Arbos, Samira
    Garcia-Cobos, Elvira
    Garcia-Ramos, Rocio
    Garcia Ruiz-Espiga, Pedro
    Herreros-Rodriguez, Jaime
    Kurtis-Urra, Monica
    Lopez-Lozano, Juan Jose
    Lopez-Manzanares, Lydia
    Martinez-Castrillo, Juan C.
    Martinez-Fernandez, Raul
    Mata, Marina
    Perez-Sanchez, Javier R.
    Posada, Ignacio J.
    Rojo, Ana
    Romero-Munoz, Juan P.
    Ruiz-Huete, Cristina
    Pilar Sanchez-Alonso, M.
    Vivancos-Matellano, Francisco
    REVISTA DE NEUROLOGIA, 2020, 71 (11) : 407 - 420
  • [39] COULD APOMORPHINE BE AN EFFECTIVE TREATMENT OPTION FOR REFRACTORY TREMOR IN PARKINSON'S DISEASE? A PILOT STUDY
    Cinar, Nilgun
    Sahin, Sevki
    Karsidag, Sibel
    NOBEL MEDICUS, 2013, 9 (02): : 100 - 103
  • [40] Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions
    Ramirez-Zamora, Adolfo
    Gee, Lucy
    Boyd, James
    Biller, Jose
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (04) : 389 - 399